Abaloparatide (Tymlos) vs NAD+ (Nicotinamide Adenine Dinucleotide)
Updated August 24, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Abaloparatide (Tymlos) and NAD+ (Nicotinamide Adenine Dinucleotide) (also searched as NAD+ (Nicotinamide Adenine Dinucleotide) vs Abaloparatide (Tymlos)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Abaloparatide (Tymlos) centers on healing, while NAD+ (Nicotinamide Adenine Dinucleotide) leans toward metabolic. On indexed research, NAD+ (Nicotinamide Adenine Dinucleotide) is ahead (Abaloparatide (Tymlos): 27 studies, Human clinical; NAD+ (Nicotinamide Adenine Dinucleotide): 31, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Abaloparatide (Tymlos) is strongest for healing; NAD+ (Nicotinamide Adenine Dinucleotide) for metabolic.
- •Evidence: Abaloparatide (Tymlos) Human clinical (27 studies) vs NAD+ (Nicotinamide Adenine Dinucleotide) Human evidence (31).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
PTH1R activation | Osteoporosis treatment
Metabolic | Energy production and cellular repair
Abaloparatide (Tymlos) vs NAD+ (Nicotinamide Adenine Dinucleotide): side-by-side
| Metric | Abaloparatide (Tymlos) | NAD+ (Nicotinamide Adenine Dinucleotide) |
|---|---|---|
| Class | Healing | Metabolic |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 27 | 31 |
| Research level | FDA Approved | Moderate Research |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.0▲ | 3.0 |
| Muscle & body comp | 1.0 | 2.0▲ |
| Metabolic & appetite | 2.0 | 5.0▲ |
| Neuro & mood | 0.0 | 4.0▲ |
| Sleep & circadian | 0.0 | 2.0▲ |
| Inflammation & immune | 1.0 | 3.0▲ |
| Skin & aesthetics | 0.0 | 1.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Abaloparatide (Tymlos) | NAD+ (Nicotinamide Adenine Dinucleotide) |
|---|---|---|
| Mechanism | PTH1R agonist | Coenzyme in redox reactions |
| Route | Subcutaneous injection | Intravenous infusion |
| Half-life | ~30 min | — |
| Time to peak | 4 hours | — |
| Duration of action | 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Abaloparatide (Tymlos)?
Abaloparatide (Tymlos) is a synthetic PTHrP analog and FDA-approved anabolic agent for osteoporosis, building bone via selective PTH1R activation.
Full Abaloparatide (Tymlos) profile, mechanism & studies →What is NAD+ (Nicotinamide Adenine Dinucleotide)?
NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.
Full NAD+ (Nicotinamide Adenine Dinucleotide) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Abaloparatide (Tymlos) | 4.0/5 effect signal |
| Muscle | NAD+ (Nicotinamide Adenine Dinucleotide) | 2.0/5 effect signal |
| Metabolic | NAD+ (Nicotinamide Adenine Dinucleotide) | 5.0/5 effect signal |
| Neuro | NAD+ (Nicotinamide Adenine Dinucleotide) | 4.0/5 effect signal |
| Sleep | NAD+ (Nicotinamide Adenine Dinucleotide) | 2.0/5 effect signal |
| Inflammation | NAD+ (Nicotinamide Adenine Dinucleotide) | 3.0/5 effect signal |
| Skin | NAD+ (Nicotinamide Adenine Dinucleotide) | 1.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Abaloparatide (Tymlos) and NAD+ (Nicotinamide Adenine Dinucleotide)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Abaloparatide (Tymlos) vs NAD+ (Nicotinamide Adenine Dinucleotide): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Abaloparatide (Tymlos) has 27 approved studies indexed (Human clinical), and NAD+ (Nicotinamide Adenine Dinucleotide) has 31 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Abaloparatide (Tymlos) or NAD+ (Nicotinamide Adenine Dinucleotide) better?
It depends on your goal. Abaloparatide (Tymlos) is strongest for healing; NAD+ (Nicotinamide Adenine Dinucleotide) for metabolic. NAD+ (Nicotinamide Adenine Dinucleotide) has more indexed studies (31). See the goal-by-goal breakdown above.
Is Abaloparatide (Tymlos) or NAD+ (Nicotinamide Adenine Dinucleotide) better for weight loss?
NAD+ (Nicotinamide Adenine Dinucleotide) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Abaloparatide (Tymlos) or NAD+ (Nicotinamide Adenine Dinucleotide) better for muscle?
NAD+ (Nicotinamide Adenine Dinucleotide) leads on the muscle & body-composition axis (2.0/5).
Which has more research, Abaloparatide (Tymlos) or NAD+ (Nicotinamide Adenine Dinucleotide)?
Abaloparatide (Tymlos) has 27 approved studies indexed (Human clinical); NAD+ (Nicotinamide Adenine Dinucleotide) has 31 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Abaloparatide (Tymlos) and NAD+ (Nicotinamide Adenine Dinucleotide)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Abaloparatide (Tymlos) vs NAD+ (Nicotinamide Adenine Dinucleotide)?
Abaloparatide (Tymlos): no community-reported effects logged yet. NAD+ (Nicotinamide Adenine Dinucleotide): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Abaloparatide (Tymlos) or NAD+ (Nicotinamide Adenine Dinucleotide) FDA-approved?
Abaloparatide (Tymlos) is FDA-approved. NAD+ (Nicotinamide Adenine Dinucleotide) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is NAD+ (Nicotinamide Adenine Dinucleotide) better than Abaloparatide (Tymlos)?
For metabolic, NAD+ (Nicotinamide Adenine Dinucleotide) has the edge; for healing, Abaloparatide (Tymlos) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed August 24, 2026.